.svg){kind=small}
Dec-2025
Sales
Trend
6-Month
Product Count
SKUs
Overview
Market Insights Snapshot
In the Canadian market, C Minor has demonstrated a notable presence in the Ontario cannabis sector, particularly within the Capsules category. Over the final quarter of 2025, C Minor's ranking fluctuated, suggesting both competitive pressure and potential growth opportunities. After starting September in the 13th position, the brand climbed to 9th place in November, highlighting a positive trend in consumer reception or market penetration. However, the brand experienced a drop back to 13th place by December, indicating potential challenges or increased competition within the category. This movement suggests that while C Minor has the potential to climb the ranks, maintaining a top position requires strategic efforts to sustain its growth trajectory.
The sales data for C Minor in Ontario also reflects interesting trends. While the brand saw an increase in sales from September through November, reaching its peak in November, the subsequent decline in December sales suggests a seasonal or market-driven fluctuation. The brand's absence from the top 30 in other states or provinces implies that its current market strength is primarily concentrated in Ontario. This could be viewed as a limitation in geographical reach, or alternatively, an opportunity for expansion into other regions. The brand's performance in the Capsules category within Ontario serves as a critical indicator of its potential to leverage existing strengths while exploring untapped markets.
Competitive Landscape
In the competitive landscape of the Ontario capsules market, C Minor experienced notable fluctuations in its ranking and sales performance from September to December 2025. Initially ranked 13th in September, C Minor climbed to 12th in October and reached an impressive 9th place in November, before slipping back to 13th in December. This temporary surge in November was marked by a significant increase in sales, surpassing competitors like Dosecann and Frank, who maintained relatively stable sales figures. However, by December, C Minor's sales had decreased, allowing Frank to overtake it in rank. Meanwhile, Pennies consistently trailed behind C Minor, despite a slight uptick in sales in November. The dynamic shifts in C Minor's ranking highlight the brand's potential to capitalize on market opportunities, although sustaining such momentum remains a challenge amidst the competitive pressures from established players like Dosecann and Frank.
Notable Products
In December 2025, the top-performing product from C Minor was CBD Fast Acting 50 Max Softgels 30-Pack (1500mg CBD) in the Capsules category, maintaining its consistent first-place rank from previous months with a sales figure of 696 units. Following closely, CBD Isolate 100 Max 3000 Oil (30ml) held its steady position at second place in the Oil category, showing a slight increase in sales compared to November. CBG:CBD 1:2 Max 2250 Ultra Formula Oil (30ml) remained in third place, although its sales decreased significantly. CBD 50 Max 3000 Oil Drops (60ml) also retained its fourth-place rank, despite a notable drop in sales. Fast Acting Max Softgels 30-Pack (300mg) did not rank in December, marking a departure from its fifth-place position in November.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
